Transaction · 0001193125-26-416953

Aslan Fred

Aslan Fred, CEO, reported an open-market or private sale at Artiva Biotherapeutics, Inc. involving 23463.000000 shares for an estimated $168879.64. Reported holdings after the transaction were 1519606.000000 shares. The stored filing text includes a detected 10b5-1 reference.

Open-market sellSEC transaction code SCEO
ARTVArtiva Biotherapeutics, Inc.
Filing timeOct 07
Trade dateOct 06, 2026
Filing · SECView on SEC
InsiderProfile
% of reported position traded1.52%Shares sold ÷ (holdings after + shares sold). Estimated position before: 1,543,069 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Price performance since filing

Close on the filing date, the pre-filing context, and the forward return at standard windows
Price at filing
$7.27
Pre-filing
1mo ago +53.9%1w ago -3.3%1d ago -1.9%
Returns since
7d30d90d180d1y

ARTV price since this filing

30 days of pre-filing context and vertical markers at the filing date plus 7d / 30d / 90d / 180d / 1y afterwards
ARTV since 2026-10-07Filed yesterday · 1 day of post-filing data
Loading…
Filing datePost-filing windows (7d, 30d, 90d, 180d, 1y)30 days of pre-filing context

Transaction facts

Stored Form 4 columns with their raw values

Non-derivative
Type
Sell
Code S
Identifier
0001193125-26-416953
Common Stock
Transaction date
Oct 06, 2026
Filed Oct 07, 2026, 08:02 PM · 1d delay
Shares
23.4k sh
$7.20 per share
Estimated value
-$168k
Computed from shares × price
Holdings after
1.51M sh
Direct

Filing signal explanations

Badges describe filing facts only — not predictions.

Cluster 14dRepeat 30dPattern $100kLarge $1.00M
Cluster Selling Direct Ownership Repeat Seller 10b5-1 Detected
0score
Filing-only score

0

Compact filing score computed from stored Form 4 facts. Version v1.

Neutral filing signal

This filing is broadly neutral on the filing-only scale. The Form 4 facts do not strongly tilt positive or negative.

Reported relationships & other filings

Form 4 relationship flags and nearby filing context

Reported roles

Chief Executive Officer

Officer YesDirector Yes10% NoOther No
Footnotes & amended
  1. F1

    The reported transactions occurred pursuant to a Rule 10b5-1 Plan adopted by the reporting person on May 13, 2026.

  2. F2

    The weighted average sale price for the transaction reported was $7.1977, and the range of prices were between $6.92 and $7.36. Upon request by the SEC staff, the Issuer, or any security holder of the…

Original filing · 0001193125-26-416953
Related transactions

0 other filings

Same reporting owner
Recent company activity

0 recent txs

ARTV